MetaVia Inc. (NASDAQ:MTVA) Short Interest Down 55.0% in March

MetaVia Inc. (NASDAQ:MTVA) saw a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 46,186 shares, a drop of 55.0% from the February 26th total of 102,676 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily trading volume, of 118,386 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Investors Weigh In On MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC boosted its stake in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the period. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Trading Up 1.5%

MTVA traded up $0.02 during trading hours on Thursday, hitting $1.32. The company’s stock had a trading volume of 53,051 shares, compared to its average volume of 265,754. The company has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $6.88. The firm has a market capitalization of $2.90 million, a PE ratio of -0.16 and a beta of 0.33. MetaVia has a fifty-two week low of $1.22 and a fifty-two week high of $23.10.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $1.64. Research analysts expect that MetaVia will post -3.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wall Street Zen lowered shares of MetaVia from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. HC Wainwright lifted their price objective on shares of MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, MetaVia has an average rating of “Hold” and a consensus target price of $36.50.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.